# A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line

Source: https://onco.cc/trials/nct07739199/  
OnCo record `nct07739199` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of izalontamab brengitecan, paclitaxel / nab-paclitaxel and carboplatin in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) is a phase 2/3, randomised interventional study registered as NCT07739199 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 200 participants, started 2026-08 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1; PD-1/VEGF bispecific antibody; Paclitaxel; Carboplatin. Conditions listed: Squamous Non-small-cell Lung Cancer. Primary outcome: Phase II: Investigator-assessed Objective Response Rate (ORR); Phase II: Investigator-assessed Progression-free Survival (PFS); Phase III: BICR-assessed Progression-free Survival (PFS). Lung eligibility wording from the registry: "Patients with locally advanced or metastatic squamous non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07739199
- Phase: 2/3
- Setting: A Phase II/III Clinical Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT07739199: https://clinicaltrials.gov/study/NCT07739199

## Connected records

- cancers: [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07739199.json